Studies Conducted at Beijing Institute of Biotechnology on Brucella melitensis Recently Reported (Biosynthesis and Immunological Evaluation of a Dual-antigen Nanoconjugate Vaccine Against Brucella Melitensis).

A recent report from the Beijing Institute of Biotechnology discusses the development of a dual-antigen nanoconjugate vaccine against Brucella melitensis, a common zoonotic disease caused by Brucella bacteria. The researchers successfully coupled polysaccharide and protein antigens to create the vaccine, which demonstrated efficient immune activation and safety in animal models. The vaccine elicited a potent antibody response and provided protection against Brucella infection for at least 18 weeks. This study presents a promising technology for delivering multiple antigens in vaccines and may have applications for other infectious diseases. [Extracted from the article]